The North America Peripheral Vascular Devices Market was worth USD 3741.11 million in 2024 and is estimated to be growing at a CAGR of 7.27%, to reach USD 5313.63 million by 2029.
The diminishing incidences of coronary angioplasties and the expanding intervention techniques have affected the surgical equipment market, mainly in North America.
The risk of restenosis in angioplasty procedures energizes the selection of novel advancements to limit post-surgical complications. Among different surgical devices, bioabsorbable stents were observed to be a breakthrough in the market. The bioabsorbable stents market is relied upon to witness a huge CAGR of 62.2% during the forecast period. The achievement accomplished during the progressing studies is additionally expected to spur market adoption.
In addition to the next-generation stent, progressed diagnostic catheters, such as optical intelligence tomography (OCT) and intravascular ultrasound (IVUS) catheters, are required to develop faster in the coming years. Compared with conventional guiding catheters, a better diagnosis of vascular health is the reason behind the critical market development. In the market, the retrievable inferior vena cava filter (IVC) possesses a remarkable market space as it turns into the best quality level for the treatment of DVT/PE in North America. Also, diminished risk of long term post-surgical complication, which is regular with changeless IVC channels, is expected to ensure a CAGR of 14.8% during the forecast time period.
Based on geography, the Canadian Peripheral Vascular Devices Market still needs a sufficient number of cardiac facilities and skilled interventionists. Also, the normal waiting time for availing heart care is horrifying in Canada; such a variable is expected to fuel the adoption of advanced minimally obstructive strategies in Canada in the coming years.
The eminent players leading the North American Peripheral Vascular Devices market incorporate Abbott Laboratories (U.S.), Cordis Corporation (U.S.), Medtronic, Inc. (U.S.), Boston Scientific Corporation (U.S.), and Covidien, Inc. (U.S.).
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region